top of page
Search
  • crallis7
    • Sep 5, 2021
    • 1 min read

JOIN US! - 2 MRC-funded positions are available in our group!

The successful researchers will work on the molecular mechanisms involved in control of cell growth, cancer drug resistance and will explore possible vulnerabilities of cells resistant to TOR signalling pathway inhibition, including resistant cancer cells.


Activation of mTOR promotes tumour growth and metastasis. While some of the mTOR inhibitors have been developed and approved to treat human cancer, more mTOR inhibitors are being evaluated in clinical trials. Due to the fundamental roles of mTOR in growth, cell cycle progression and anabolism within all eukaryotes, resistance to mTOR inhibition itself is a major problem, partly attributed to the large heterogeneity of cancer cells.

Results from this project will lead in a better understanding of nutrient- and growth factor-dependent cellular growth and will highlight the key candidates for targeting resistant cancer cells.


For more information visit job websites:

1. https://lnkd.in/gUYPPDuW

2. https://lnkd.in/gKEQZst3

6 views0 comments

Recent Posts

See All

Check the original research article preprint on Bioarxiv: The AMPK-TORC1 signalling axis regulates caffeine-mediated DNA damage checkpoint override and cell cycle effects in fission yeast | bioRxiv

Congratulations to all! Check the review on: Interplays of AMPK and TOR in Autophagy Regulation in Yeast - PubMed (nih.gov)

Check our new publication! Nutrient-Response Pathways in Healthspan and Lifespan Regulation. Dabrowska A, Kumar J, Rallis C.Cells. 2022 May 6;11(9):1568. doi: 10.3390/cells11091568.

bottom of page